Susquehanna International Group, LLP Cytokinetics Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $604,396 - $709,888	11,800 Added 3.52%	347,100 $18.3 Million
Q2 2024 Aug 15, 2024	SELL	$47.86 - $75.05 $13.5 Million - $21.1 Million	-281,600 Reduced 45.65%	335,300 $18.2 Million
Q1 2024 May 07, 2024	SELL	$63.75 - $108.06 $127 Million - $215 Million	-1,991,200 Reduced 76.35%	616,900 $43.3 Million
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $65.9 Million - $205 Million	2,450,200 Added 1551.74%	2,608,100 $218 Million
Q3 2023 Nov 14, 2023	BUY	$29.46 - $36.61 $3.66 Million - $4.55 Million	124,400 Added 371.34%	157,900 $4.65 Million
Q2 2023 Aug 11, 2023	SELL	$32.62 - $40.75 $1.01 Million - $1.26 Million	-30,900 Reduced 47.98%	33,500 $1.09 Million
Q1 2023 May 16, 2023	SELL	$33.36 - $45.71 $1.31 Million - $1.8 Million	-39,300 Reduced 37.9%	64,400 $2.27 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $894,250 - $1.28 Million	-25,000 Reduced 19.43%	103,700 $4.75 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $770,800 - $1.09 Million	20,000 Added 18.4%	128,700 $6.24 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $481,806 - $694,664	14,200 Added 15.03%	108,700 $4.27 Million
Q1 2022 May 16, 2022	BUY	$29.74 - $46.0 $529,372 - $818,800	17,800 Added 23.21%	94,500 $3.48 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $759,135 - $1.02 Million	22,100 Added 40.48%	76,700 $3.5 Million
Q3 2021 Nov 15, 2021	SELL	$18.54 - $35.74 $943,686 - $1.82 Million	-50,900 Reduced 48.25%	54,600 $1.95 Million
Q2 2021 Aug 11, 2021	BUY	$19.79 - $26.99 $1.1 Million - $1.5 Million	55,600 Added 111.42%	105,500 $2.09 Million
Q1 2021 May 17, 2021	SELL	$18.57 - $25.68 $1.48 Million - $2.04 Million	-79,600 Reduced 61.47%	49,900 $1.16 Million
Q4 2020 Feb 16, 2021	SELL	$15.26 - $28.61 $1.44 Million - $2.7 Million	-94,200 Reduced 42.11%	129,500 $2.69 Million
Q3 2020 Nov 16, 2020	BUY	$20.58 - $28.96 $3.4 Million - $4.78 Million	165,000 Added 281.09%	223,700 $4.84 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $107,040 - $236,544	-9,600 Reduced 14.06%	58,700 $1.38 Million
Q1 2020 May 15, 2020	SELL	$8.75 - $16.3 $114,625 - $213,530	-13,100 Reduced 16.09%	68,300 $805,000
Q4 2019 Feb 14, 2020	BUY	$7.95 - $11.84 $321,975 - $479,520	40,500 Added 99.02%	81,400 $864,000
Q3 2019 Nov 14, 2019	SELL	$10.82 - $14.25 $99,544 - $131,100	-9,200 Reduced 18.36%	40,900 $465,000
Q2 2019 Aug 14, 2019	BUY	$7.95 - $11.25 $92,220 - $130,500	11,600 Added 30.13%	50,100 $564,000
Q1 2019 May 15, 2019	BUY	$5.95 - $10.19 $46,410 - $79,482	7,800 Added 25.41%	38,500 $311,000
Q4 2018 Feb 14, 2019	SELL	$5.91 - $9.29 $134,748 - $211,811	-22,800 Reduced 42.62%	30,700 $194,000
Q3 2018 Nov 14, 2018	BUY	$6.4 - $9.85 $148,480 - $228,520	23,200 Added 76.57%	53,500 $527,000
Q2 2018 Aug 14, 2018	SELL	$6.9 - $9.9 $358,800 - $514,800	-52,000 Reduced 63.18%	30,300 $251,000
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $67,680 - $94,470	9,400 Added 12.89%	82,300 $593,000
Q4 2017 Feb 14, 2018	SELL	$7.25 - $15.65 $36,250 - $78,250	-5,000 Reduced 6.42%	72,900 $594,000
Q3 2017 Nov 14, 2017	BUY	$12.0 - $15.0 $934,800 - $1.17 Million	77,900	77,900 $1.13 Million

Others Institutions Holding CYTK

# of Institutions

410

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

Black Rock Inc. New York, NY

14.7M
Shares

$737 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$591 Million
0.01% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

9.69M
Shares

$487 Million
0.31% of portfolio
Wellington Management Group LLP Boston, MA

7.77M
Shares

$390 Million
0.07% of portfolio
State Street Corp Boston, MA

6.46M
Shares

$324 Million
0.01% of portfolio

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.73B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account